Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer

Acta Medica Okayama

Volumn 62, Issue 1, 2008, Pages 9-13

  Ebara, Shin ^a   Katayama, Yoshihisa ^a   Tanimoto, Ryuta ^a   Edamura, Kohei ^a   Nose, Hiroyuki ^a   Manabe, Daisuke ^a   Kobayashi, Tomoko ^a   Kobayashi, Yasuyuki ^a   Kobuke, Makoto ^a   Takemoto, Mitsuhiro ^a   Saika, Takashi ^a   Nasu, Yasutomo ^a   Kanazawa, Susumu ^a   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Brachytherapy; Localized prostate cancer; Prostate specific antigen; Urinary morbidity

Indexed keywords

RADIOACTIVE IODINE;

AGED; ARTICLE; BRACHYTHERAPY; CLINICAL TRIAL; ECHOGRAPHY; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORBIDITY; PATIENT SELECTION; PROSTATE TUMOR; RADIATION DOSE; RISK FACTOR; TREATMENT OUTCOME;

AGED; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MORBIDITY; PATIENT SELECTION; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RISK FACTORS; TREATMENT OUTCOME;

EID: 41549139341     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Ragde H, Elgamal AA, Snow PB, Brandt J, Bartolucci AA, Nadir BS and Korb LJ: Ten-year disease-free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer (1998) 83: 989-1001.
2. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, Landin K and Cavanagh W: Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate cancer. Cancer (1997) 80: 442-453.
3. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester J, Hoak DC, Cavanagh W and Landin K: Brachytherapy for clinically localized prostate cancer: results at 7 and 8 year follow-up. Semin Surg Oncol (1997) 13: 438-443.
4. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH and Allen ZA: Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys (2005) 62: 437-447.
5. Wilson S: Downsizing and Prostate Cancer. Reviews in Urology suppl 7 (2004) 6: S19-S24.
6. Stone NN and Stock RG: Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology (2007) 69: 338-342.
7. Iannuzzi CM, Stock RG and Stone NN: PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer. Radiat Oncol Invest (1999) 7: 30-35.
8. Critz FA: Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer. J Urol (2002) 168: 2434-2438.
9. Critz FA, Levinson AK, Williams WH, Holladay DA and Holladay CT: The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology (1997) 49: 322-326.
10. Grimm P, Blasko JC, Sylvester JE, Meier RM and Cavanagh W: 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy. Int J Radiat Oncol Biol Phys (2001) 51: 31-40.